NGS Automation Market Worth $1.33 billion by 2029

Meticulous Research®-leading global market research company published a research report titled, 'NGS Automation Market By Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Global Forecast to 2029'

Access Complete Free Sample PDF Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5271

According to this latest publication from Meticulous Research®, the NGS automation market is expected to grow at a CAGR of 13.4% from 2022 to reach $1.33 billion by 2029. The growth of this market is attributed to factors such as the increasing demand for automation in NGS workflow, the rising incidences of cancer, and the increasing R&D investments and healthcare expenditure.

In addition, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market.

However, the high cost of automation workstations is expected to restrain the growth of this market to a notable extent. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges for the growth of this market.

NGS Automation Market: Future Outlook

The NGS automation market is segmented based on product, application, sequencing type, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on product, in 2022, the workstation/robotic platform segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the increasing demand for the automation of NGS workflow, the rising adoption of automation workstations/robotic platforms by pharmaceutical and biotechnology companies and in diagnostic laboratories, and the increasing number of funding by governments for drug discovery and research.

Based on application, in 2022, the drug discovery segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the increasing utilization of NGS for identifying novel drug targets and developing therapeutic techniques that target specific genes and proteins, such as targeted therapies, gene therapies, and oligonucleotide therapies, resulting in the increased demand for automation of NGS workflow.

Based on sequencing type, in 2022, the whole genome sequencing segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the advantages of whole-genome sequencing (WGS) in discovery applications, such as identifying causative variants and novel genome assembly, and the ability of this method to detect single nucleotide variants, insertions/deletions, copy number changes, and large structural variants. In addition, the increasing application of WGS in cancer diagnosis and targeted therapy in precision oncology drives the demand for NGS automation in whole-genome sequencing.

Check complete table of contents with list of table and figures: https://www.meticulousresearch.com/product/ngs-automation-market-5271

In 2022, based on end user, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the market. The large share of this segment is attributed to the rising R&D expenditure and the growing demand for new drug discoveries using advanced technologies. Additionally, the financial capability of these companies to invest in NGS automation workstations and acquire trained personnel contributes to the growth of the pharmaceutical and biotechnology companies segment.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and the Middle East & Africa.

In 2022, North America is estimated to account for the largest share of the NGS automation market, followed by Europe and Asia-Pacific. North America's major market is attributed to the rising demand for NGS automation among researchers and scientists, the governments' increasing support and investments to enhance genome sequencing infrastructure in the region, and the growing number of R&D investments by pharmaceutical and biopharmaceutical companies.

The key players operating in the NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).

Have Any Query? Ask To Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5271

Key questions answered in the report-

1. Which are the high-growth market segments in terms of product, application, sequencing type, end user, and region/country?
2. What was the historical market size for the NGS automation market across the globe?
3. What are the market forecasts and estimates for the period 2022-2029?
4. What are the major drivers, restraints, opportunities, and challenges in the global NGS automation market?
5. Who are the major players in the NGS automation market?
6. How is the competitive landscape, and who are the market leaders in the global NGS automation market?
7. What are the recent developments in the global NGS automation market?
8. What are the different strategies adopted by the major players in the global NGS automation market?
9. What are the geographical trends and high growth regions/countries?

Exciting news! We are thrilled to announce an incredible opportunity for you!

For a limited time only, we are delighted to offer an exclusive flat 30% discount on all our remarkable research reports. It's our way of showing appreciation for your continuous support and commitment to staying informed. This remarkable discount allows you to unlock a wealth of valuable insights and expert analysis at an unbeatable price. Whether you're a business professional, an academic researcher, or an avid learner, this offer is tailor-made to enhance your knowledge and empower your decision-making.

Quick Buy : https://www.meticulousresearch.com/Checkout/27804657

ABOUT Us-
We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Contact Us:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

This release was published on openPR.